L'intérêt à découvert pour Warby Parker donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Warby Parker. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Warby Parker (NYSE:WRBY) Stock, Rapport sur les intérêts à découvert

WARBY PARKER INC-CLASS A

Warby Parker

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Warby Parker Inc

Retailer Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) may provide a better picture of the impact of tariffs on consumers when the company reports first-quarter financial results before <a href="https://www.benzinga.com/earnings">market open Thursday.</a>
Here are the analyst estimates, a look at what experts are saying ahead of the report and key items to watch.
Earnings Estimates: Analysts expect Walmart to report first-quarter revenue of $165.88 billion. That&#8217;s up from $161.51 billion in last year's first quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in more than 10 straight quarters.
Analysts expect Walmart to report earnings per share of 58 cents, down from 60 cents per share in Q1 2024.
The company has beaten analyst estimates for earnings per share in five straight quarters and nine of the last ten quarters overall. The lone non-beat was earnings in line with estimates.
The company&#8217;s guidance calls for first-quarter sales to be up 3% to 4% year over year. Earnings per share range between 57 cents and 58 cents.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45272436/marjorie-taylor-greene-goes-stock-shopping-again-here-are-50-stocks-the-congresswoman-bought">Marjorie Taylor Greene Goes Stock Shopping Again: 50+ Stocks The Congresswoman Bought</a>
What Experts Are Saying: In a recent note, Telsey Advisory analyst Joseph Feldman said Walmart could benefit from grocery market share gains and improving e-commerce progress in the <a href="https://www.benzinga.com/news/large-cap/25/05/45357178/walmart-analysts-strategy-curbs-price-hikes-despite-tariffs">first quarter.</a>
The analyst maintained an Outperform rating and price target for $115.
Feldman said Walmart could gain wallet share from several groups, including higher-income consumers. The analyst said Amazon and Costco showed trends of first-quarter sales being stronger for categories like electronics.
Feldman said Walmart should navigate the uncertain macroeconomic environment effectively.
Bank of America analyst Robert Ohmes said Walmart is well-equipped to handle tariffs with its pricing and automation strategies, inventory management and strong supplier relationships.
The analyst maintained a Buy rating with a $120 price target ahead of the quarterly earnings.
Ohmes said Walmart's groceries are less likely to be impacted by tariffs.
Freedom Capital Markets Chief Global Strategist Jay Woods highlighted the importance of Walmart's financial results for the market in his weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
"Walmart could be one of the most telling stocks when it comes to tariff impacts when they report on Thursday," Woods said.
Woods said Walmart was cautious with guidance after the last quarter.
"Investors will be closely watching this report for strategies on managing tariff-related challenges, maintaining competitive pricing, and supply chain issues that may make stocking shelves more of a challenge."
Key Items to Watch: Tariffs commentary will undoubtedly be the biggest item in Walmart's earnings and conference call.
Outside of tariffs, investors and analysts could also look at commentary on the company's Walmart+ membership program. The subscription-based service was responsible for around 50% of online spending in the U.S. last fiscal year. This could make it a strong source of ecommerce and recurring revenue.
A report said the program is seeing increased spending per subscriber and also higher shopping frequency rates from subscribers.
Walmart+ has also helped the retailer post 11 consecutive quarters of double-digit online sales growth in the United States.
Global e-commerce sales were up 16% year-over-year in Q4; this will be a key area to watch in Q1.
WMT Price Action: Walmart stock was up 1.3% to $97.11 on Wednesday versus a 52-week trading range of $59.47 to $105.30. Walmart stock is up 7.9% year-to-date in 2025 and up over 60% in the last year. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44226602/walmart-ceo-says-consumers-changing-spending-due-to-inflation-egg-prices-the-money-runs-out-before-the-month-is-gone-people-are-buying-smaller-pack-sizes">Walmart CEO Says Consumers Changing Spending Due To Inflation, Egg Prices: &#8216;The Money Runs Out Before The Month Is Gone … People Are Buying Smaller Pack Sizes&#8217;</a><a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
Image: Shutterstock<a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"> </a>

Analyst Color

Price Target

Previews

Reiteration

Analyst Ratings

Trading Ideas

Walmart Q1 Earnings Preview: Why Retailer Will Have 'One Of The Most Telling' Reports On Tariff Impact

News

Management

STWD

SREIT Appoints Nora Creedon As President And CEO; Succeeds SREIT Appoints Nora Creedon Chief Executive Officer

NVDA closes near high for the day after reversing early weakness
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14201052/Screenshot-2025-05-14-at-4.10.21%E2%80%AFPM-1021x1024.png" alt="" class="wp-image-12962" /></figure>
Nvidia Inc. (NVDA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:35 AM on May 14th, a significant trading signal occurred for Nvidia Inc., (NVDA) as it demonstrated a Power Inflow at a price of $132.50. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Nvidia&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Nvidia&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for NVDA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $132.50. The returns on the High price ($135.44) and Close price ($135.34) after the Power Inflow are respectively 2.2% and 2.1%. They were close today but that is not always the case.
Results are not indicative of future results

Equities

WIIM

Technicals

Opinion

Signals

Nvidia Rises 2.2% After Key Signal, Reversing Early Weakness

Earnings

Earnings Misses

CTOR

Citius Oncology Q2 EPS $(0.11) Misses $(0.09) Estimate

SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) reported quarterly losses of $(0.03) per share. The company reported $5.10 million in sales this quarter.

SSII

SS Innovations Q1 EPS $(0.03), Sales $5.10M

Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) reported quarterly losses of $(0.28) per share. The company reported $165.26 thousand in sales this quarter.

KITT

Nauticus Robotics Q1 EPS $(0.28) Up From $(3.96) YoY, Sales $165.26K Down From $464.35M YoY

Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 91.13 percent increase over losses of $(2.03) per share from the same period last year.

CLDI

Calidi Biotherapeutics Q1 EPS $(0.18) Misses $(0.15) Estimate

Stock Split

SQFT

SQFTP

SQFTW

Presidio Property Trust Announces 1-For-10 Reverse Stock Split

- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 -
- Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time -
- Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 -
- Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET -
Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>), a clinical stage gene editing company utilizing its novel proprietary ARCUS&#xAE; platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company's first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) and highlighted a PBGENE-DMD poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana.

Biotech

General

DTIL

Precision BioSciences Accelerates Development Of First-in-Class In Vivo Gene Editing Therapy PBGENE-DMD For Duchenne Muscular Dystrophy Targeting Exons 45–55 Hot Spot, IND/CTA Submission Planned For 2025 And Clinical Data Expected In 2026

Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $12.46 million which beat the analyst consensus estimate of $12.00 million by 3.81 percent. This is a 7.30 percent increase over sales of $11.61 million the same period last year.

Earnings Beats

GWRS

Global Water Resources Q1 EPS $0.02 Beats $0.01 Estimate, Sales $12.46M Beat $12.00M Estimate

CSCO

Cisco Systems CFO Scott Herren To Retire Effective July 26, 2025; Mark Patterson To Succeed

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 15 years by 4.76% on an annualized basis producing an average annual return of 16.75%. Currently, First Citizens BancShares has a market capitalization of $26.08 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 15 years ago, it would be worth $984.91 today based on a price of $1962.92 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747255516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

Here's How Much $100 Invested In First Citizens BancShares 15 Years Ago Would Be Worth Today

Battalion Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BATL#AMEX">BATL</a>) reported quarterly losses of $(0.35) per share. This is a 84.38 percent increase over losses of $(2.24) per share from the same period last year. The company reported $47.48 million in sales this quarter. This is a 4.80 percent decrease over sales of $49.87 million the same period last year.

BATL

Battalion Oil Q1 EPS $(0.35) Up From $(2.24) YoY, Sales $47.48M Down From $49.87M YoY

BZAI

Blaize Holdings Q1 EPS $(1.61), Sales $1.01M

Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 81.9 percent increase over losses of $(2.21) per share from the same period last year.

ORKA

Oruka Therapeutics Q1 EPS $(0.40) Beats $(0.52) Estimate

Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $(1.74) by 595.4 percent.

JBIO

Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate

Contango Ore (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#AMEX">CTGO</a>) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.21) by 795.24 percent. This is a 12.15 percent increase over losses of $(2.14) per share from the same period last year.

CTGO

Contango Ore Q1 EPS $(1.88) Misses $(0.21) Estimate

Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) reported quarterly losses of $(0.71) per share. This is a 29.09 percent decrease over losses of $(0.55) per share from the same period last year.

AARD

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Enpro Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) today announced the pricing of its previously announced offering of senior notes due 2033 (the "Senior Notes"). The face value of the Senior Notes is $450 million with an annual interest rate of 6.125%. The Senior Notes were priced at 100.0% of the face value. The offer was made in the United States to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in reliance on Regulation S under the Securities Act. The Senior Notes offering is expected to close on May 29, 2025.
Enpro intends to use the net proceeds from the offering to fund the redemption of all of its outstanding 5.75% senior notes due 2026 (the "Outstanding Notes"), to repay a portion of the borrowings under its senior secured revolving credit facility used to fund the repayment on April 9, 2025 of all of its then-outstanding term loans under its senior secured credit facility, and to pay fees and expenses in connection with the offering. The conditional redemption of the Outstanding Notes was announced by Enpro on May 13, 2025.

Offerings

Enpro Inc. Prices Offering Of $450M 6.125% Senior Notes Due 2033

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(1.22) per share. This is a 86.75 percent increase over losses of $(9.21) per share from the same period last year.

ENVB

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Press Releases

Warby Parker Announces Second Quarter 2024 Results

Warby Parker Announces Participation in the Goldman Sachs 31st Annual Global Retailing Conference

Warby Parker to Announce Third Quarter 2024 Financial Results November 7, 2024

Warby Parker Announces Third Quarter 2024 Results

Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

Warby Parker to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Warby Parker Announces Fourth Quarter and Full Year 2024 Results

Target and Warby Parker Team Up to Bring Stylish, Affordable Eyewear to More Consumers

Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

Warby Parker Announces First Quarter 2025 Results

WRBY

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports

BARK

Build-A-Bear Workshop

Bath & Body Works

Barnes & Noble Education, Inc Common Stock

Barnes & Noble Education

Chewy

Dick's Sporting Goods

Envela

National Vision Holdings, Inc. - Common Stock

National Vision Holdings

Five Below

1-800-FLOWERS.COM, Inc. - Class A Common Stock

1-800-Flowers.com

MarineMax

Leslies

PetMed Express

Park Ha Biological Technology Co., Ltd. - ordinary shares

Park Ha Biological Tech

Sally Beauty Holdings, Inc. (Name to be changed from Sally Holdings, Inc.) Common Stock

Comments

Warby Parker

Intérêt court

Warby Parker (NYSE:WRBY) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL